The 10 Largest US Health Startup Funding Rounds of 2026 So Far

The ten largest US health startup funding rounds of 2026 so far ranged from $250 million to $1.5 billion each. Announced between January 1 and late June, this group spans the whole of health: a medical-device maker, a fitness wearable, a Medicare Advantage insurer, longevity and cancer biotechs, an eye-disease drug developer, and two artificial intelligence (AI) companies. Together, these ten rounds moved more than $4.5 billion into privately held US health companies in under six months.

The pace reflects a broader rise in health funding.

Digital health alone drew about $4.0 billion across 110 US deals in the first quarter, and twelve rounds of $100 million or more accounted for most of that capital, according to Rock Health.[1] Counted more broadly, and including AI drug discovery, CB Insights put first-quarter global digital-health funding at $7.4 billion.[2] Biopharma financing across the first five months of 2026 reached roughly $49.5 billion, the third-highest total for that stretch on record.[3]

How this list was built

This ranking counts US-headquartered companies only. It includes private funding rounds announced between January 1 and June 27, 2026. It leaves out initial public offerings, public stock sales, debt-only deals, cash that arrived through an acquisition, and grants. Where two rounds tie on size, the earlier announcement is listed first.

By that standard, several of the year's biggest health deals sit outside the list. Isomorphic Labs raised $2.1 billion in May, but it is based in London. Earendil Labs disclosed $787 million, but it runs much of its operations from China. Apogee Therapeutics arranged up to $1.3 billion, but it is a public company and the money came as royalty and debt financing rather than a venture round. Orca Bio announced $250 million in January, but the figure combined separate rounds and one of them closed in December 2025. Each is a real deal. None fits the US-only, in-window, private-round test used here.

The ranking at a glance

1. MiRus: $1.5 Billion From Boston Scientific

MiRus builds implants and surgical devices out of a molybdenum-rhenium alloy it calls MoRe. The metal is strong and contains no nickel, which some patients react to. Its products span spine and orthopedic hardware and structural-heart devices, including the SIEGEL balloon-expandable replacement aortic valve. On May 18, 2026, Boston Scientific paid $1.5 billion for a stake of about 34% in the privately held company, plus an option to buy its transcatheter heart-valve business outright.[4][5]

MiRus was founded by Jay S. Yadav, MD, an interventional cardiologist who serves as chief executive. Before MiRus, Jay S. Yadav founded CardioMEMS, a heart-failure sensor company later acquired by St. Jude Medical and then Abbott, and AngioGuard, which was bought by Cordis and Johnson & Johnson. Boston Scientific was the sole investor in this round. The structure, a large minority stake plus an option on a product line, is the kind of arrangement that sometimes precedes a full acquisition.[4]

2. WHOOP: $575 Million Series G

WHOOP sells a screen-free wristband and a subscription app that track heart rate, sleep, strain, and recovery around the clock. The band has no display, so members read their data in the app. Athletes wear it to guide training and rest, and a growing base of everyday users wears it to track general health. On March 31, 2026, the Boston company raised $575 million in a Series G round that valued it at $10.1 billion.[6]

WHOOP was founded in 2012 by Will Ahmed, John Capodilupo, and Aurelian Nicolae, who started the company while Will Ahmed was an undergraduate at Harvard. Will Ahmed is the chief executive. Collaborative Fund led the Series G. The round also drew three sovereign investors: 2PointZero Group, the Qatar Investment Authority, and Mubadala Investment Company. A group of elite athletes and the medical-device maker Abbott, a strategic investor, also took part.[6][7]

3. NewLimit: $435 Million Series C

NewLimit develops medicines meant to make old cells behave like young ones. Its drugs deliver combinations of regulatory proteins into cells to reset which genes those cells switch on and off, an approach known as epigenetic reprogramming. Its first program targets the liver and is moving toward a first human trial. On June 2, 2026, the South San Francisco company raised $435 million in a Series C round at a valuation of about $3.1 billion.[8][9]

NewLimit was co-founded in 2021 by Brian Armstrong, the co-founder and chief executive of Coinbase, with Blake Byers, a bioengineer and former partner at the venture firm GV, and Jacob Kimmel, a stem-cell and computational biologist who spent years at the Alphabet-backed lab Calico. Jacob Kimmel serves as chief executive. Founders Fund led the round. Thrive Capital, Greenoaks, Kleiner Perkins, Valor Equity Partners, and Eli Lilly's venture arm took part, as did the technologists Nat Friedman and Daniel Gross.[8][9]

4. Ollin Biosciences: $330 Million Series B

Ollin Biosciences develops an injectable drug for diseases that damage the back of the eye. Its lead candidate, OLN324, is aimed at diabetic macular edema and wet age-related macular degeneration, two leading causes of vision loss. The company plans to test it against the established eye drugs Eylea and Vabysmo in late-stage trials. On June 24, 2026, the Austin company raised $330 million in a Series B round.[10][11]

Ollin Biosciences was co-founded by Jason Ehrlich, MD, PhD, an ophthalmologist and drug developer who serves as chief executive. TCGX and ARCH Venture Partners co-led the round. Andreessen Horowitz, Mubadala Capital, and Monograph Capital also invested. The size of a Series B is unusual. It reflects how expensive late-stage eye-disease trials have become and how large the market for the leading drugs already is.[10][11]

5. Devoted Health: $317 Million Series F-Prime

Devoted Health runs a Medicare Advantage health plan and delivers care to its members through its own clinical teams. The company combines an insurance plan, a medical group called Devoted Medical, a technology platform, and dedicated service "Guides" who help members find care and manage conditions. As of January 2026, it served more than 466,000 members across 29 states. On January 30, 2026, the Waltham, Massachusetts company announced a $317 million Series F-Prime round, part of $366 million raised across two tranches, at a valuation of about $12.6 billion.[12][13]

Devoted Health was founded in 2017 by the brothers Todd Park and Ed Park. Ed Park, the chief executive, was previously chief operating officer of Athenahealth. Todd Park, the executive chairman, co-founded Athenahealth and Castlight Health and served as US Chief Technology Officer under President Barack Obama. The Space Between led the round, alongside the London investment firm Centricus. New backers included GV, Morgan Health, a unit of JPMorgan Chase, Franklin Venture Partners, VanEck, and MIG Private Equity.[12][13]

6. Parabilis Medicines: $305 Million Series F

Parabilis Medicines designs drugs that reach cancer targets older medicines cannot. Its Helicon peptides are stabilized protein fragments built to bind proteins inside cells that have long resisted treatment. The lead drug, FOG-001, blocks a cancer-driving protein called beta-catenin and is in clinical trials. On January 8, 2026, the Cambridge, Massachusetts company raised $305 million in a Series F round.[14][15]

Parabilis Medicines was founded by Gregory Verdine, PhD, a longtime Harvard chemist and repeat biotech founder who also started Warp Drive Bio. The company was previously known as FogPharma. RA Capital Management, Fidelity, and Janus Henderson co-led the round. venBio, Cormorant Asset Management, ARCH Venture Partners, and General Catalyst also took part.[14][15]

7. Verily: $300 Million And Independence From Alphabet

Verily builds software that pools patient data from many health systems and runs AI models on it to spot disease earlier and support medical research. It began in 2015 as a health project inside Google X and then became an Alphabet subsidiary. On March 19, 2026, the Dallas company raised $300 million and stepped out on its own, with Alphabet giving up majority ownership.[16][17]

Verily was founded by Andrew Conrad, a molecular biologist who served as its first chief executive. It is now led by Stephen Gillett, a former executive at Google, Starbucks, and the security company Chronicle. Series X Capital led the $300 million round. Alphabet kept a minority stake. The raise is one of the larger health software rounds of the year. It marks the point where a decade-old corporate research effort became a standalone company.[16][17]

8. Beeline Medicines: $300 Million Series A

Beeline Medicines develops drugs for autoimmune and inflammatory diseases. It came out of stealth in April 2026 with five precision-medicine programs already in hand, all licensed from the pharmaceutical company Bristol Myers Squibb. The company launched with its pipeline already built. On April 15, 2026, the Boston company raised $300 million in a Series A round.[18][19]

Beeline Medicines was created by the investment firm Bain Capital, which assembled the company around the Bristol Myers Squibb assets and led the financing. Beeline is run by Saqib Islam, the former chief executive of SpringWorks Therapeutics, a cancer drug company. A $300 million Series A is rare. It reflects a model in which an investor builds a company around proven assets before opening it to outside capital.[18][19]

9. OpenEvidence: $250 Million Series D

OpenEvidence runs an AI search engine that answers doctors' clinical questions using peer-reviewed medical literature. A physician types a question and gets an answer with citations to published studies. The company says more than a quarter of US doctors use the tool. On January 21, 2026, the Miami company raised $250 million in a Series D round that valued it at $12 billion.[20][21]

OpenEvidence was founded in 2021 by Daniel Nadler and Zack Ziegler. Daniel Nadler, the chief executive, earlier founded the financial-data company Kensho, which S&P Global bought. Thrive Capital and DST Global co-led the Series D, and Sequoia Capital took part. The round was one of several in 2026 that pushed the company's total funding past $795 million.[20][21]

10. Anagram Therapeutics: $250 Million From Blackstone

Anagram Therapeutics develops an oral drug that replaces a digestive enzyme some patients cannot make on their own. Its lead candidate, ANG003, treats exocrine pancreatic insufficiency, a condition common in cystic fibrosis and pancreatic cancer. The company says ANG003 could cut a patient's load from up to 40 pills a day to one tablet per meal. It also says the drug could be the first such therapy not derived from pig pancreas. On May 7, 2026, the Massachusetts company received a $250 million investment from Blackstone Life Sciences.[22][23]

Anagram Therapeutics is a clinical-stage company co-founded by Robert Gallotto, an experienced pharmaceutical executive who serves as president and chief executive. Blackstone Life Sciences provided the full $250 million. The investment followed more than $30 million in earlier support from the Cystic Fibrosis Foundation, which helped fund the drug's first trials.[22][23]

Just outside the top ten

Science Corporation, an eye-implant maker led by Neuralink co-founder Max Hodak, raised $230 million in a Series C round in March at a $1.5 billion valuation. Its PRIMA chip is implanted in the eye and works with camera glasses to restore sight to people with advanced macular degeneration. The round places it at number 11, just below this list.[24]

What This Means For Patients And Physician-Led Practices

Five of these ten companies build products that shape how care is delivered. OpenEvidence puts current medical evidence in front of physicians during a visit. Verily and WHOOP gather the kind of long-run health data that primary care has rarely had at hand. Devoted Health runs a Medicare Advantage plan and its own care teams. MiRus makes the implants that specialists place. The money is moving toward earlier detection, faster answers, and longer-running data on each person.

The other five are drug developers. NewLimit, Parabilis, Ollin, Beeline, and Anagram are building treatments for aging, cancer, eye disease, autoimmune conditions, and rare digestive disorders. These rounds take years to reach a patient, but they shape which therapies a future doctor will be able to offer.

For a patient choosing a physician, the useful question is which doctors use these advances well. A good concierge or direct primary care (DPC) physician reads the evidence, follows wearable and lab data over time, and refers to the right specialist. That is often the doctor who turns this kind of progress into better care. NextMD lists physician-led concierge and DPC practices for patients searching nationwide, so finding that kind of doctor takes a single search.

FAQ

What was the largest US health startup funding round of 2026 so far?

The largest was MiRus, which received $1.5 billion from Boston Scientific on May 18, 2026, in exchange for a stake of about 34% and an option to buy its heart-valve business. MiRus makes implants from a nickel-free molybdenum-rhenium alloy. It is the only confirmed US health private investment above $1 billion in the first half of 2026.

How were these funding rounds ranked?

They are ranked by the total size of a single private funding round announced between January 1 and June 27, 2026. The list counts US-headquartered companies only. It excludes initial public offerings, public stock sales, debt-only deals, cash from an acquisition, and grants. Where two rounds tie on size, the earlier announcement is listed first.

Why isn't Isomorphic Labs on the list?

Isomorphic Labs raised $2.1 billion in May 2026, one of the largest private health raises in the world this year. It is left off because it is headquartered in London, and this list covers US-headquartered companies only. Two other large raises are left off for similar window-and-location reasons: Earendil Labs at $787 million, which runs much of its operations from China, and Orca Bio at $250 million, whose financing combined separate rounds and one of which closed in December 2025.

Were biotech and drug companies counted alongside digital health?

Yes. This ranking covers all of health, so drug developers, device makers, AI companies, and care services compete on the same list. Because drug and device companies tend to raise the largest single rounds, they fill much of the top ten. A list limited to digital health and software would look different and would feature companies such as OpenEvidence and Verily near the top.

What do Series A, B, C, and later rounds mean?

These letters mark the order of a company's priced funding rounds. A Series A is usually an early institutional round, and each later letter is a larger, later-stage raise. The letter marks the company's stage, and the dollar figure is the size of the round. They are separate. Beeline Medicines raised $300 million in a Series A, while many Series C rounds are smaller.

A Note On Method

This article was built from a sweep of funding news across biotech, digital health, medical devices, and health services, then checked against primary sources. Each round's amount, date, headquarters, founders, and lead investors were confirmed against company press releases and reporting from outlets including STAT News, Fierce Biotech, Fierce Healthcare, TechCrunch, CNBC, Reuters, and Business Wire. Rounds that could not be confirmed as US-headquartered, private, and announced within the window were left off. Funding figures and valuations reflect what was reported as of June 27, 2026.

Sources

1. Rock Health. (2026). Q1 2026 Funding Overview: Capital Continues Concentrating, and Four Other Market Signals. https://rockhealth.com/insights/q1-2026-funding-overview-capital-continues-concentrating-and-four-other-market-signals/

2. HIT Consultant. (2026). Digital Health Funding Q1 2026: AI, M&A Rebound (citing CB Insights, State of Digital Health Q1'26). https://hitconsultant.net/2026/04/20/digital-health-funding-q1-2026-ai-ma-rebound/

3. BioWorld. (2026). Hemab soars 89% on debut as biopharma IPOs stay strong in May. https://www.bioworld.com/articles/731832-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may

4. Boston Scientific. (2026). Boston Scientific announces strategic investment in MiRus, LLC. https://news.bostonscientific.com/2026-05-18-Boston-Scientific-announces-strategic-investment-in-MiRus-LLC

5. Crunchbase News. (2026). The Biggest Funding Rounds: Medical Devices, Futuristic AI Gadgets And Frontier Labs. https://news.crunchbase.com/venture/biggest-funding-rounds-medical-devices-futuristic-ai-gadgets-frontier-labs-mirus/

6. WHOOP. (2026). WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform. https://www.whoop.com/us/en/press-center/whoop-announces-series-g-funding/

7. MedTech Dive. (2026). Whoop raises $575M, adds Abbott as strategic investor. https://www.medtechdive.com/news/whoop-raises-575m-adds-abbott-as-strategic-investor/816229/

8. STAT News. (2026). Longevity startup NewLimit announces $435 million clinical trial financing. https://www.statnews.com/2026/06/02/longevity-startup-newlimit-announces-435-million-clinical-trial-financing/

9. NewLimit. (2026). NewLimit raises $435M led by Founders Fund. https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders

10. STAT News. (2026). Ophthalmology biotech Ollin Biosciences launches with $330 million. https://www.statnews.com/2026/06/24/ophthalmology-biotech-ollin-biosciences/

11. Fierce Biotech. (2026). Ollin hauls $330M to enlist Vabysmo challenger in Phase 3 eye disease gauntlet. https://www.fiercebiotech.com/biotech/ollin-hauls-330m-enlist-vabysmo-challenger-phase-3-eye-disease-gauntlet

12. Devoted Health. (2026). Devoted Health Grows to Improve the Health and Well-Being of More Americans. https://www.devoted.com/resources/2026-growth/

13. Galen Growth. (2026). The American Powerplay: U.S. Digital Health Funding in Q1 2026. https://www.galengrowth.com/the-american-powerplay-u-s-digital-health-funding-in-q1-2026/

14. Business Wire. (2026). Parabilis Medicines Announces $305 Million Series F Financing. https://www.businesswire.com/news/home/20260108088855/en/

15. Fierce Biotech. (2026). Parabilis Medicines rockets ahead with $305M fundraise to upend the status quo. https://www.fiercebiotech.com/biotech/parabilis-medicines-rockets-ahead-305m-fundraise-upend-status-quo

16. Fierce Healthcare. (2026). Verily banks $300M to accelerate AI road map, transitions to independent company. https://www.fiercehealthcare.com/health-tech/verily-banks-300m-accelerate-ai-roadmap-transitions-independent-company

17. D Magazine. (2026). Healthcare AI Platform Verily Lands $300M to Accelerate Its Push Into Precision Health. https://www.dmagazine.com/healthcare-business/2026/03/healthcare-ai-platform-verily-lands-300m-to-accelerate-its-push-into-precision-health/

18. Bain Capital. (2026). Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune Disease. https://www.baincapital.com/news/beeline-medicines-debuts-deliver-category-leading-precision-therapies-people-living-autoimmune

19. Fierce Biotech. (2026). Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS. https://www.fiercebiotech.com/biotech/bain-backed-beeline-medicines-buzzes-out-stealth-300m-and-5-programs-bms

20. CNBC. (2026). 32. OpenEvidence — CNBC Disruptor 50. https://www.cnbc.com/2026/05/19/openevidence-cnbc-disruptor-50-ranking.html

21. Reuters. (2026). Medical AI startup OpenEvidence doubles valuation to $12 billion in latest round. https://www.reuters.com/business/healthcare-pharmaceuticals/medical-ai-startup-openevidence-doubles-valuation-12-billion-latest-round-2026-01-21/

22. Pulse 2.0. (2026). Anagram Therapeutics Raises $250 Million From Blackstone Life Sciences To Advance Oral Enzyme Replacement Therapy. https://pulse2.com/anagram-therapeutics-raises-250-million-from-blackstone-life-sciences-to-advance-oral-enzyme-replacement-therapy/

23. Fierce Biotech. (2026). Blackstone invests $250M in Anagram to reduce burden of CF complication. https://www.fiercebiotech.com/biotech/blackstone-invests-250m-anagram-reduce-burden-cf-complication

24. TechCrunch. (2026). Science Corp. raises $230M as it races to bring its brain implant to market. https://techcrunch.com/2026/03/05/science-corp-closes-230m-round-as-it-pushes-to-get-its-brain-implant-to-patients/